Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for NULOJIX
- Advancing Transplantation Outcomes in Children
- Abatacept Conversion in Kidney Transplantation
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, a
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
- Belatacept in De Novo Heart Transplantation
- Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
- Treg Modulation With CD28 and IL-6 Receptor Antagonists
- Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
- Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
- Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.
- Bela 8 Week Dosing
- Safety Profile of Nulojix in Home Infusion Settings
- Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
- Belatacept 3 Month Post Transplant Conversion Study
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- Regimen Optimization Study
- Belatacept for Renal Transplant Recipients With Delayed Graft Function
- Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
- Efficacy of Belatacept in Reducing DSA
- Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
- Belatacept Therapy for the Failing Renal Allograft
- Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
- Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
- A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
- Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
- Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
- Belatacept Early Steroid Withdrawal Trial
- Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients
- Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
- Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
- Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
- Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- Islet Transplantation Using Abatacept
Clinical trials list
click for details